Comerica Bank
EGRX

Comerica Bank’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Comerica Bank’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-491
Closed -$2.57K – 3839
2023
Q4 		$2.57K Sell
491
-135
-22% -$1.33K ﹤0.01% 3467
2023
Q3 		$9.87K Buy
+626
New +$11.2K ﹤0.01% 3209
2022
Q4 		$208K Sell
6,345
-1,950
-24% -$62K ﹤0.01% 2054
2022
Q3 		$257K Sell
8,295
-1,310
-14% -$48.1K ﹤0.01% 1997
2022
Q2 		$418K Sell
9,605
-375
-4% -$17.2K ﹤0.01% 1901
2022
Q1 		$502K Buy
9,980
+1,080
+12% +$51.8K ﹤0.01% 1867
2021
Q4 		$414K Sell
8,900
-1,050
-11% -$54.4K ﹤0.01% 1930
2021
Q3 		$520K Sell
9,950
-419
-4% -$20.6K ﹤0.01% 1932
2021
Q2 		$504K Sell
10,369
-786
-7% -$32.4K ﹤0.01% 2022
2021
Q1 		$491K Sell
11,155
-565
-5% -$26.2K ﹤0.01% 2032
2020
Q4 		$559K Sell
11,720
-481
-4% -$22.5K ﹤0.01% 1971
2020
Q3 		$571K Buy
12,201
+1,847
+18% +$80.8K ﹤0.01% 1857
2020
Q2 		$516K Buy
10,354
+583
+6% +$29.1K ﹤0.01% 1850
2020
Q1 		$502K Buy
9,771
+299
+3% +$15K ﹤0.01% 1730
2019
Q4 		$520K Buy
9,472
+24
+0.3% +$1.43K ﹤0.01% 1876
2019
Q3 		$589K Sell
9,448
-100
-1% -$5.62K ﹤0.01% 1809
2019
Q2 		$520K Sell
9,548
-671
-7% -$35K ﹤0.01% 1862
2019
Q1 		$488K Sell
10,219
-504
-5% -$22.4K ﹤0.01% 1897
2018
Q4 		$444K Sell
10,723
-49
-0.5% -$2.52K ﹤0.01% 1908
2018
Q3 		$627K Buy
10,772
+1,930
+22% +$146K 0.01% 1801
2018
Q2 		$725K Buy
8,842
+130
+1% +$8.18K 0.01% 1797
2018
Q1 		$481K Buy
8,712
+111
+1% +$6.46K ﹤0.01% 1920
2017
Q4 		$514K Sell
8,601
-1,094
-11% -$60.9K ﹤0.01% 1910
2017
Q3 		$504K Buy
9,695
+1,469
+18% +$88.9K ﹤0.01% 1896
2017
Q2 		$599K Sell
8,226
-769
-9% -$62.9K ﹤0.01% 1779
2017
Q1 		$814K Buy
8,995
+550
+7% +$40.9K 0.01% 1691
2016
Q4 		$585K Buy
8,445
+415
+5% +$30.1K ﹤0.01% 1810
2016
Q3 		$517K Buy
+8,030
New +$445K ﹤0.01% 1771

Other funds holding EGRX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Comerica Bank's EGRX Position: Q1 2024 in Review

Comerica Bank sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2024, closing a stake of 491 shares — an estimated $2.57K sold.

Comerica Bank first reported a position in EGRX in Q3 2016 and held it in 28 quarters. The position peaked at $814K in Q1 2017. 91 funds tracked by Wall St. Rank hold EGRX as of Q1 2024.

  • Comerica Bank reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
  • Comerica Bank sold 491 Eagle Pharmaceuticals, Inc. shares in Q1 2024, an estimated $2.57K.
  • Comerica Bank first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2016 and held it in 28 quarters.
  • Comerica Bank's Eagle Pharmaceuticals, Inc. position peaked at $814K in Q1 2017.
  • 91 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2024.

Based on Comerica Bank's 13F filing for Q1 2024, filed 16 May 2024.